ABOS
Acumen Pharmaceuticals, Inc. [ABOS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ABOS Stock Summary
Top 10 Correlated ETFs
ABOS
Top 10 Correlated Stocks
ABOS
In the News
ABOS Financial details
Company Rating
-
Market Cap
224.7M
Income
-50.54M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
51
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-4.92
Forward P/E
-
PEG
-16.4
P/S
-
P/B
0.84
P/C
-
P/FCF
-5.48
Quick Ratio
35.33
Current Ratio
35.85
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.03
EPS next Y
-
EPS next Q
-
EPS this Y
8%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
40.11%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
16.67%
-
-
-
-
SMA20
34.69%
SMA50
55.66%
SMA100
54.21%
Inst Own
-
Inst Trans
-
ROA
-17%
ROE
-23%
ROC
-0.2%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.81-11.31
52W High
-70.27%
52W Low
+227%
RSI
64.25
Rel Volume
1.09
Avg Volume
361.14K
Volume
392.73K
Perf Week
-1.21%
Perf Month
17.2%
Perf Quarter
159.52%
Perf Half Y
142.22%
-
-
-
-
Beta
0.082
-
-
Volatility
0.07%, 0.37%
Prev Close
-0.91%
Price
3.27
Change
-1.8%
Company Profile
- Volume Average 361.14K
- Market Capitalization 224.7M
- Employee 51
- CEO Mr. Daniel J. O'Connell M.B.A.
- Headquarters Charlottesville,VA,US
- IPO Date 2021-07-01
-
Website
https://acumenpharm.com 
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
